Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities

Manuela Porru, Luca Pompili, Carla Caruso, Annamaria Biroccio, Carlo Leonetti

Research output: Contribution to journalArticlepeer-review

Abstract

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.

Original languageEnglish
Article number57
JournalJournal of Experimental and Clinical Cancer Research
Volume37
Issue number1
DOIs
Publication statusPublished - Mar 13 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities'. Together they form a unique fingerprint.

Cite this